A Phase II Study of Efficacy and Safety of Paclitaxel and Cisplatin Every 2 Weeks as the First-line Treatment of Patients With Ovarian Cancer Stage Ic-IV.
- To investigate the efficacy and safety of paclitaxel and cisplatin as first-line
chemotherapy in patients with stage IC-IV ovarian epithelial cancer.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV and cisplatin IV once every 2 weeks. Treatment repeats every
2 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
Masking: Open Label, Primary Purpose: Treatment
Sergei A. Tjulandin, MD, PhD
Russian Academy of Medical Sciences Cancer Research Center